Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
A $44m up-front for the tumour-activated IL-12 XTX301 will help keep Xilio going until 2025.
The latest first-in-human study initiations will be of interest to followers of D2M Therapeutics, Nested and Volastra.
The takeover of AnHeart centres on advancing the latter’s targeted lung cancer project taletrectinib.
The decision highlights the fact that Regeneron is still doing dose-finding work for odronextamab.
A just revealed clinical trial listing shows Ascentage’s BCL-2 inhibitor being compared against an outdated standard of care.
The company takes another project from Taris into phase 3 as it chases a $5bn market.